Palantir will work with HHS's Office of the chief information officer and provide its software platform to help manage the US COVID-19 vaccine distribution strategy, enable international distribution, and improve the equity and efficacy of vaccine programs.
The contract duration is for one year.
Palantir's software enables organizations to improve their data-driven decision-making process by integrating disparate data sources into a single common operating picture.
Palantir was commissioned in mid-2020 by the Department of Health and Human Services to build Tiberius, a software platform it uses to track vaccine production, distribution, and administration across the United States.
For this renewed contract, Palantir will continue to support Tiberius, which gives local, state and federal health officials a comprehensive platform to track vaccine distribution and administration.
It will also help US officials facilitate the distribution of American-donated vaccines in an effort to halt the progression of the pandemic worldwide.
Palantir has played a key role in mitigating the global COVID-19 pandemic in the US and abroad, supporting more than 100 organizations in their response to the pandemic, including with the UK's National Health Service and across the US government and military.
Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments.
From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV